Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3810477 in Healthy Male and Female Trial Participants (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 30 Jun 2025
At a glance
- Drugs BI 3810477 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Jun 2025 Status changed from not yet recruiting to recruiting.
- 29 May 2025 New trial record